GR 127935 hydrochloridePotent, selective 5-HT1B/1D antagonist CAS# 148642-42-6 |
2D Structure
- GPR120 modulator 1
Catalog No.:BCC1599
CAS No.:1050506-75-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 148642-42-6 | SDF | Download SDF |
PubChem ID | 11497466 | Appearance | Powder |
Formula | C29H32ClN5O3 | M.Wt | 534.06 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water | ||
Chemical Name | N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]benzamide;hydrochloride | ||
SMILES | CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)N5CCN(CC5)C.Cl | ||
Standard InChIKey | SRVVUYIJVBLEJI-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C29H31N5O3.ClH/c1-19-17-23(28-30-20(2)37-32-28)9-11-25(19)21-5-7-22(8-6-21)29(35)31-24-10-12-27(36-4)26(18-24)34-15-13-33(3)14-16-34;/h5-12,17-18H,13-16H2,1-4H3,(H,31,35);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent and selective 5-HT1B/1D receptor antagonist (pKi values are 8.5 for both guinea pig 5-HT1D and rat 5-HT1B receptors). Displays > 100-fold selectivity over 5HT1A, 5-HT2A, 5-HT2C receptors and other receptor types. Centrally active following oral administration. |
GR 127935 hydrochloride Dilution Calculator
GR 127935 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.8724 mL | 9.3622 mL | 18.7245 mL | 37.449 mL | 46.8112 mL |
5 mM | 0.3745 mL | 1.8724 mL | 3.7449 mL | 7.4898 mL | 9.3622 mL |
10 mM | 0.1872 mL | 0.9362 mL | 1.8724 mL | 3.7449 mL | 4.6811 mL |
50 mM | 0.0374 mL | 0.1872 mL | 0.3745 mL | 0.749 mL | 0.9362 mL |
100 mM | 0.0187 mL | 0.0936 mL | 0.1872 mL | 0.3745 mL | 0.4681 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Fmoc-Prolinol
Catalog No.:BCC2710
CAS No.:148625-77-8
- 3-O-Methylquercetin
Catalog No.:BCN1660
CAS No.:1486-70-0
- 3-O-Methylquercetin tetraacetate
Catalog No.:BCN1659
CAS No.:1486-69-7
- 3,5-Dihydroxyergosta-7,22-dien-6-one
Catalog No.:BCN1658
CAS No.:14858-07-2
- Pregabalin
Catalog No.:BCN2175
CAS No.:148553-50-8
- GRK2i
Catalog No.:BCC6048
CAS No.:148505-03-7
- MNS
Catalog No.:BCC3943
CAS No.:1485-00-3
- JMV 390-1
Catalog No.:BCC5922
CAS No.:148473-36-3
- L-732,138
Catalog No.:BCC6821
CAS No.:148451-96-1
- Prion Protein 106-126 (human)
Catalog No.:BCC6027
CAS No.:148439-49-0
- (+)-Matairesinol
Catalog No.:BCN7021
CAS No.:148409-36-3
- Docetaxel Trihydrate
Catalog No.:BCC1535
CAS No.:148408-66-6
- L-733,060 hydrochloride
Catalog No.:BCC5707
CAS No.:148687-76-7
- SB 204070
Catalog No.:BCC5752
CAS No.:148688-01-1
- Tyrphostin AG 879
Catalog No.:BCC4514
CAS No.:148741-30-4
- (R)-2-Methylcysteine HCl
Catalog No.:BCC4017
CAS No.:148766-37-4
- Carboxy-PTIO, potassium salt
Catalog No.:BCC6789
CAS No.:148819-94-7
- Bismuth Subsalicylate
Catalog No.:BCC3739
CAS No.:14882-18-9
- Rutamarin
Catalog No.:BCN7509
CAS No.:14882-94-1
- Ivabradine HCl
Catalog No.:BCC4350
CAS No.:148849-67-6
- YM 511
Catalog No.:BCC6002
CAS No.:148869-05-0
- HATU
Catalog No.:BCC2813
CAS No.:148893-10-1
- Fmoc-L-Arg(Aloc)2-OH
Catalog No.:BCC2564
CAS No.:148893-34-9
- 3-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl-2-propenal
Catalog No.:BCC8600
CAS No.:148901-68-2
Genetic regulation of extracellular serotonin by 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse.[Pubmed:11504805]
J Pharmacol Exp Ther. 2001 Sep;298(3):1083-91.
The regulation of extracellular levels of 5-hydroxytryptamine (serotonin) (5-HT) in the striatum and ventral hippocampus was studied using in vivo microdialysis in awake, unrestrained wild-type 5-HT(1A) and 5-HT(1B) receptor knockout mice. Systemic administration of the selective serotonin reuptake inhibitor fluoxetine evoked a significant dose-dependent increase in extracellular 5-HT in both the striatum and hippocampus at both 2.5 mg/kg (i.p.) and 20 mg/kg (i.p.) in wild-type mice. In 5-HT(1A) receptor knockout mice, the response to 2.5 mg/kg fluoxetine was significantly augmented in the striatum but not the hippocampus, whereas the response to 20 mg/kg fluoxetine was significantly greater in both brain regions. In 5-HT(1B) receptor knockout mice, the increase of extracellular 5-HT was augmented in the hippocampus but not the striatum at both doses of fluoxetine. The response pattern to fluoxetine alone in 5-HT receptor mutant mice corresponded with the effects of fluoxetine given with either the 5-HT(1A) receptor antagonist WAY 100635 (0.1 mg/kg i.p.) or the 5-HT(1B/1D) receptor antagonist GR 127935 (0.056 mg/kg) in wild-type mice. These results indicate common topographical regulation of 5-HT release in different brain regions by genetic mutation and pharmacological challenges. The 5-HT(1A) autoreceptor plays a larger role in regulating 5-HT release in the striatum and possibly other brain regions innervated by the dorsal raphe nucleus, whereas the role of the 5-HT(1B) receptor is relatively greater in the hippocampus and possibly other brain regions innervated by the median raphe nucleus.
Blockade of porcine carotid vascular response to sumatriptan by GR 127935, a selective 5-HT1D receptor antagonist.[Pubmed:8733580]
Br J Pharmacol. 1996 May;118(1):85-92.
1. It has previously been shown that the antimigraine drug, sumatriptan, a putative 5-HT1D receptor agonist, decreases porcine common carotid and arteriovenous anastomotic blood flows, but slightly increases the arteriolar (capillary) blood flow to the skin and ears. Interestingly, such responses, being mediated by 5-HT1-like receptors, are resistant to blockade by metergoline, which, in addition to displaying a very high affinity for (and occasionally intrinsic efficacy at) the 5-HT1D receptor subtypes, blocks (with lower potency than methiothepin) some 5-HT1D receptor-mediated vascular responses. These findings raise doubts whether sumatriptan-sensitive 5-HT1-like receptors mediating changes in the distribution of porcine carotid blood flow are identical to cloned 5-HT1D receptors. With the recent advent of the potent and selective 5-HT1D receptor antagonist, GR127935, we have examined in the present study whether the carotid vascular effects of sumatriptan in the pig are amenable to blockade by GR127935. 2. In animals pretreated with saline, sumatriptan (30, 100 and 300 micrograms kg-1, i.v.) reduced the total carotid and arteriovenous anastomotic blood flows in a dose dependent manner. In contrast, sumatriptan increased blood flow to the skin, ears and fat, although the total capillary fraction was not significantly affected. 3. While GR127935 pretreatment (0.25 and 0.5 mg kg-1) itself slightly reduced the total carotid and arteriovenous anastomotic blood flows, carotid vasoconstrictor responses to sumatriptan were either partly (0.25 mg kg-1) or completely (0.5 mg kg-1) blocked by the compound. In GR127935 pretreated animals, the sumatriptan-induced increases in blood flow to the skin, ears and fat were also attenuated. 4. Taken together, the results suggest that arteriovenous anastomotic constriction and, possibly, arteriolar dilatation in the skin, ears and fat by sumatriptan are mediated by 5-HT1D receptors. Therefore, vascular 5-HT1-like receptors in the porcine carotid bed appear to be identical to 5-HT1D receptors.